Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
Warner Chilcott Q2 Profit Up 66%; Lifts FY09 EPS Outlook - Update
8/7/2009 11:15 AM  ET

RELATED NEWS
Warner Chilcott Prices Secondary Offering Of 20 Mln Ordinary Shares At $22.25 - Quick Facts
Warner Chilcott Announces Secondary Equity Offering Of 20 Mln Shares - Quick Facts
Warner Chilcott Q3 Profit Soars On Licensing Deal Gains - Update
Amended: Warner Chilcott Q3 Profit Surges - Quick Facts
Warner Chilcott Q3 09 Earnings Conference Call At 8:00 AM ET
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Pharmaceutical company Warner Chilcott Ltd. (WCRX: News ), Friday, posted 66% higher profit for the June quarter on an increase in revenues resulting from higher sales of Doryx, Loestrin 24 FE and Estrace cream as well as lower expenses. The company also raised its earnings guidance for the full year 2009, while affirming its revenue outlook.

Net income increased to $56.02 million or $0.22 per share from $33.57 million or $0.13 per share in the same quarter last year.

Results for the quarter included special charges of $52.22 million on amortization of intangible assets and $0.96 million on amortization and write-offs of deferred loan costs, net of tax.

Excluding charges, cash net income increased 29.6% to $109.20 million or $0.44 per share for the latest quarter.

On average, twelve analysts polled by Thomson Reuters expected the company to report earnings of $0.40 per share. Analysts' estimates typically exclude special items.

Revenue for the three months increased 7.1% to $250.82 million from $234.22 million in the comparable quarter last year. Analysts had a consensus revenue estimate of $252.09 million for the quarter.

Oral contraceptive Loestrin 24 FE generated revenues of $58.0 million, up 15.5% a year ago. Dermatology product Doryx generated $44.9 million revenues, up 41.6% from the year-ago period. Hormone therapy product Estrace cream recorded revenues of $28.2 million, or up 33.1% a year ago.
Revenues increased mainly on net sales of $28.0 million contributed by Doryx, Loestrin 24 FE and Estrace cream, partially offset by net sales decline of other products, primarily Estrostep FE, Sarafem and Femhrt.

Research and development expenses for the quarter were $11.9 million, a decrease 4.8% from last year. Net interest expense for the quarter declined 38.2% to $15.2 million from $24.6 million in the prior year quarter.

For the six months, net income increased to $99.36 million or $0.40 per share from net income of $67.23 million or $0.27 per share for the same period a year ago. Revenue for the six months increased to $496.80 million from $463.69 million for the comparable period in 2008.

Looking ahead, the company affirmed its full-year 2009 revenue guidance in the range of $1.015 billion to $1.025 billion. The company has also raised its GAAP net income guidance to $186 million - $199 million from the earlier range $174 million - $186 million.

The company anticipates cash net income per share for the year to be in the range of $1.60 to $1.65, higher than previously forecasted range of $1.55 to $1.60.

To receive FREE breaking news email alerts for Warner Chilcott Limited and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

74  FDA Approves Bristol-Myers' Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder - Update
73  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
72  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
71  CF Nominees Enter Terra's Board - Update
70  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
69  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
68  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
67  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
66  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
65  Covidien's Pain Drug NDA Review Extended By FDA - Update
64  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
63  Cloud Peak Energy Prices IPO At $15/shr - Update
62  Met-Pro Q3 Profit Plunges - Update
61  Boston Scientific Receives FDA's 510 (k)Clearance For WallFlex Fully Covered Esophageal Stent - Update
60  Pfizer Granted FDA Approval For Intravenous Formulation Of Revatio - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS